Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ifinatamab deruxtecan + pembrolizumab
- Development stage
- Unknown
- Lead developer
- Daiichi Sankyo
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Ifinatamab deruxtecan + pembrolizumab is an investigational combination therapy currently in clinical development for the treatment of advanced cancers, primarily esophageal squamous cell carcinoma and non-small cell lung cancer. **Ifinatamab deruxtecan** (I-DXd, DS-7300a, MK-2400) is an antibody-drug conjugate (ADC) targeting B7-H3 (CD276) on tumor cells; it delivers a topoisomerase I inhibitor payload via a cleavable linker, leading to targeted cytotoxicity. **Pembrolizumab** (Keytruda, MK-3475) is a monoclonal antibody that blocks the interaction between PD-1 and its ligands (PD-L1/PD-L2), enhancing T-cell mediated immune responses against tumors. The combination aims to exploit both **direct tumor cell kill by ADC** and **enhanced immune checkpoint inhibition**, with early-phase trials underway to evaluate safety and efficacy in multiple cancer indications[1][4][7][10].
- Brand names
- Keytruda
- Other names
- I-DXd + pembrolizumabDS-7300a + MK-3475
02
Targets
TOP1 (DNA Topoisomerase I)B7-H3PDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on ifinatamab deruxtecan + pembrolizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ifinatamab deruxtecan + pembrolizumab.